18 recruiting, 13 completed, 12 unknown, 5 active not recruiting. 19 Phase 2, 10 Phase 1, 9 Not applicable, 3 Phase 3, 1 Early Phase 1.
Follow Adenocarcinoma, Mucinous: new trials by email Literature Review of Adenocarcinoma, Mucinous trials Research Report on Adenocarcinoma, Mucinous
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA) Ivonescimab, IP PTX - Phase II, Ivonescimab | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 30 | 2027-01-16 | 2026-08-27 |
| Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE) Intestinal, Multivisceral or Modified Multivisceral Transplantation, Alemtuzumab, Tacrolimus - Secondary Malignant Neoplasm of Retroperitoneum, Secondary Malignant Neoplasm of Peritoneum | Phase 2 | Not yet recruiting | Case Comprehensive Cancer Center | 20 | 2026-11-01 | 2026-09-24 |
| TLR9 Immunotherapy for Peritoneal Carcinomatosis ACM-CpG - Malignant Ascites, Colorectal Adenocarcinoma | Phase 1 | Recruiting | Brown University | 24 | 2026-08-25 | 2026-10-01 |
| Ph II Intraperitoneal Paclitaxel + System Therapy in GI Ca w/Peritoneal Carcinomatosis (STOPGAP-B) Paclitaxel Q2W, Paclitaxcel Q3W - Esophageal Carcinoma, Gastric Cancer (Diagnosis) | Phase 2 | Recruiting | University of California, Irvine | 55 | 2026-08-04 | 2026-08-31 |
| Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer Samuraciclib + Gemcitabine & Nab-Paclitaxel - Pancreas Ductal Adenocarcinoma, Pancreas Cancer, Metastatic | Phase 1 / Phase 2 | Not yet recruiting | University Health Network, Toronto | 67 | 2026-07-01 | 2026-06-24 |
| Metformin in Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms Metformin - Appendiceal Mucinous Neoplasm, Pseudomyxoma Peritonei | Phase 2 | Recruiting | University of California, Irvine | 15 | 2026-06-18 | 2026-07-13 |
| Molecular Profiling for Risk Stratification in Appendiceal Cancer DNA Methylation Profiling, m6A Epitranscriptomic Profiling - Appendiceal Cancer, Appendiceal Adenocarcinoma | Recruiting | City of Hope Medical Center | 400 | 2026-05-01 | 2026-06-29 | |
| The Appendix Cancer PMP Research Foundation Natural History Study/Patient Registry Appendix Cancer, Pseudomyxoma Peritonei | Recruiting | Appendix Cancer Pseudomyxoma Peritonei Research Foundation | 10000 | 2026-02-02 | 2026-08-17 | |
| Proactive Temperature Management in CRS-HIPEC for Prevention of Delirium Proactive Goal-Directed Temperature Management, Standard Reactive Temperature Management - Pseudomyxoma Peritonei, Postoperative Delirium (POD) | Not applicable | Not yet recruiting | Aerospace Center Hospital | 174 | 2026-02-01 | 2026-01-30 |
| Ventral Hernias Following Cytoreductive Surgery : Incidence, Risk Factors and Surgical Management. Ventral Hernias, Cytoreductive Surgery | Recruiting | Jules Bordet Institute | 500 | 2026-01-20 | 2026-03-05 | |
| One vs Three HIPEC Cycles After CRS for Pseudomyxoma Peritonei One HIPEC session, Three HIPEC sessions - Pseudomyxoma Peritonei | Not applicable | Recruiting | Beijing Tsinghua Chang Gung Hospital | 132 | 2025-11-01 | 2026-01-09 |
| Pseudovax - A Cancer Vaccine for Patients With Pseudomyxoma Peritonei Pseudovax, Molgramostim, Tislelizumab - Pseudomyxoma Peritonei | Early Phase 1 | Recruiting | Oslo University Hospital | 10 | 2025-10-13 | 2026-01-14 |
| Flura-seq for Evaluating the Effects of Different Hyperthermic Intraperitoneal Chemotherapy Regimens on the Transcriptome of Pseudomyxoma Peritonei intravenously inject with 5-FU (400 mg/m2) - Pseudomyxoma Peritonei | Not applicable | Completed | Beijing Tsinghua Chang Gung Hospital | 36 | 2025-02-17 | 2026-01-06 |
| Study to Evaluate the Non-inferiority of Low-dose HIPEC Versus High-dose HIPEC in the Treatment of PMP (HIPEC-PMP) Mitomycin c - Pseudomyxoma Peritonei | Phase 3 | Recruiting | University of Southampton | 176 | 2024-12-04 | 2026-02-19 |
| Metronomic Neoadjuvant Capecitabine and Cyclophosphamide in HUGE Pseudomyxoma Peritonei Patients Capecitabine 1250 mg/m2 /day - Cyclophosphamide 50Mg/day - Pseudomyxoma Peritonei | Phase 2 | Recruiting | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 31 | 2024-11-22 | 2025-01-30 |
| Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery CSL511 Fibrinogen concentrate (human), Cryoprecipitate - Acquired Fibrinogen Deficiency | Phase 3 | Recruiting | CSL Behring | 90 | 2024-10-01 | 2026-10-13 |
| A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors APL-5125 - Colorectal Cancer, Cholangiocarcinoma | Phase 1 | Completed | Apollo Therapeutics Ltd | 27 | 2024-06-18 | 2026-10-05 |
| A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors INCB099280, axitinib - Advanced Solid Tumors | Phase 1 / Phase 2 | Terminated | Incyte Corporation | 5 | 2024-04-16 | 2026-06-04 |
| A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma Dexamethasone, Diphenhydramine, Famotidine - Metastatic Appendiceal Adenocarcinoma, Intraperitoneal Paclitaxel | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 39 | 2024-01-30 | 2026-07-16 |
| Head-to-head Comparison of Positron Nuclide Radio-labeled FAPI and 18F-FDG PET/CT in Patients With Malignant Tumors FAPI PET/CT - Renal Cell Carcinoma, Gastric Cancer | Not applicable | Unknown | Guangdong Provincial People's Hospital | 30 | 2024-01-11 | 2024-01-22 |
Showing 20 of 56. Sign in to see all of them.
Pseudomyxoma Peritonei (37) · Colorectal Neoplasms (13) · Appendiceal Neoplasms (12) · Peritoneal Neoplasms (11) · Stomach Neoplasms (7) · Neoplasms (6) · Ovarian Neoplasms (6) · Fallopian Tube Neoplasms (5) · Neoplasms, Cystic, Mucinous, and Serous (5) · Adenocarcinoma (4) · Carcinoma (4) · Endometrial Neoplasms (4) · Neoplasm Metastasis (4) · Pancreatic Neoplasms (4)
Neoplasms by Histologic Type (53) · Neoplasms, Glandular and Epithelial (53) · Adenocarcinoma (52) · Carcinoma (52) · Neoplasms, Cystic, Mucinous, and Serous (51) · Neoplasms (50) · Neoplasms by Site (32) · Digestive System Diseases (29) · Digestive System Neoplasms (28) · Gastrointestinal Diseases (21) · Gastrointestinal Neoplasms (21) · Intestinal Diseases (19) · Intestinal Neoplasms (19) · Colonic Diseases (15)
Fluorouracil (3) · Gemcitabine (3) · Hyperthermic Intraperitoneal Chemotherapy (3) · Leucovorin (3) · Mitomycin (3) · Oxaliplatin (3) · Acetylcysteine (2) · Bevacizumab (2) · Bromelains (2) · Capecitabine (2) · Carboplatin (2) · Disulfides (2) · Immunoglobulin G (2) · Nivolumab (2) · Paclitaxel (2)
M.D. Anderson Cancer Center (5) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (3) · Royal Marsden NHS Foundation Trust (3) · Beijing Tsinghua Chang Gung Hospital (2) · Case Comprehensive Cancer Center (2) · Hospices Civils de Lyon (2) · Mercy Medical Center (2) · National Cancer Institute (NCI) (2) · Oslo University Hospital (2) · University of California, Irvine (2) · University of Southampton (2) · Aerospace Center Hospital (1) · Albert Einstein College of Medicine (1) · Andreana Holowatyj, PhD, MSCI (1) · Apollo Therapeutics Ltd (1)
United States (27) · United Kingdom (9) · Italy (5) · Canada (4) · China (4) · France (4) · Belgium (3) · Norway (3) · Spain (3) · Germany (2) · South Korea (2) · Switzerland (2) · Argentina (1) · Australia (1) · Austria (1)
Gina Brown (3) · Armando Sardi, MD (2) · Beth Helmink, MD (2) · Alessandra Raimondi, MD (1) · Alvaro Arjona Sanchez, MD (1) · Andreana N Holowatyj, PhD, MSCI (1) · Armando Sardi, M.D. (1) · Barbara Andersen, PhD (1) · Brendan Moran (1) · Christian Kersten, MD, PhD (1) · Deborah Shelton (1) · Diana Tait (1) · Dr. Erin P. Ward, MD (1) · Edward Levine, MD (1)
PMID 36410913, PMID 23844722, PMID 25822672, PMID 28212684, PMID 28438473, PMID 30473706, PMID 30862609, PMID 31262599, PMID 31722153, PMID 31969335, PMID 32826114, PMID 32873454, PMID 33362722, PMID 33882143, PMID 34380663, PMID 34716198, PMID 35389428, PMID 37185961, PMID 38243705, PMID 38358334, PMID 39067873, PMID 39343510, PMID 39417692, PMID 39583952, PMID 39856213, PMID 40402690, PMID 40588371, PMID 41672597, PMID 41892875, PMID 41995270, PMID 42499790
2019 (1), 2023 (1), R21CA135005 (1), U10CA027469 (1), U10CA180868 (1), U10CA180888 (1)